# A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

> **NCT05485753** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** GNC-038

## Key facts

- **NCT ID:** NCT05485753
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485753, "A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05485753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*